文献速递心脑血管急症

卒中后卵圆孔未闭封堵治疗的疗效异质性:随机试验个体患者数据汇总分析

Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在18至60岁卵圆孔未闭相关卒中患者中,封堵术的卒中复发风险降低因PASCAL分类(因果关联可能性)而异,PASCAL分类有潜力指导个体化决策。

该研究由SCOPE联盟汇总了全部6项比较卵圆孔未闭封堵联合药物治疗与单纯药物治疗的随机临床试验的个体患者数据,共纳入3740例患者,随访中位57个月。药物治疗组卒中年化发生率为1.09%,封堵组为0.47%(校正HR 0.41,95%CI 0.28-0.60)。亚组分析显示,RoPE评分低 vs 高者的HR分别为0.61和0.21(交互P=0.02);PASCAL分类为不太可能、可能、很可能者的HR分别为1.14、0.38和0.10(交互P=0.003)。结论认为封堵术的卒中风险降低在不同PASCAL分类组间存在差异,该分类系统有潜力指导个体化决策。

要点

  • 在3740例18至60岁卵圆孔未闭相关卒中患者中,封堵联合药物治疗较单纯药物治疗降低卒中复发风险(校正HR 0.41,95%CI 0.28-0.60)。
  • PASCAL分类为不太可能、可能、很可能者的HR分别为1.14(95%CI 0.53-2.46)、0.38(95%CI 0.22-0.65)、0.10(95%CI 0.03-0.35),交互P=0.003。
  • RoPE评分低 vs 高者的HR分别为0.61(95%CI 0.37-1.00)和0.21(95%CI 0.11-0.42),交互P=0.02。
  • 2年绝对风险降低在PASCAL不太可能、可能、很可能组分别为-0.7%(95%CI -4.0%至2.6%)、2.1%(95%CI 0.6%-3.6%)、2.1%(95%CI 0.9%-3.4%)。
  • 封堵相关不良事件在PASCAL不太可能组总体更高;随机化45天后新发心房颤动的绝对风险增加在不太可能、可能、很可能组分别为4.41%(95%CI 1.02%-7.80%)、1.53%(95%CI 0.33%-2.72%)、0.65%(95%CI -0.41%-1.71%)。

适用人群与场景

  • 18至60岁、卵圆孔未闭相关卒中患者,来自6项比较卵圆孔未闭封堵联合药物治疗与单纯药物治疗的随机临床试验,共3740例。

诊断标准与关键阈值

  • RoPE评分:10分制评分系统,评分越高反映年龄越轻且无血管危险因素。
  • PASCAL分类系统:结合RoPE评分与高危卵圆孔未闭特征(房间隔瘤或大分流),将患者分为因果关联不太可能、可能、很可能3类。

研究设计与关键结果

  • 研究类型:SCOPE联盟汇总的个体患者数据汇总分析,纳入全部6项随机临床试验,共3740例参与者,试验于2000年至2017年在全球开展。
  • 中位随访57个月(IQR 24-64),共发生121例结局事件。
  • 药物治疗组卒中年化发生率为1.09%(95%CI 0.88%-1.36%),封堵组为0.47%(95%CI 0.35%-0.65%),校正HR 0.41(95%CI 0.28-0.60)。
  • RoPE评分低 vs 高者的HR分别为0.61(95%CI 0.37-1.00)和0.21(95%CI 0.11-0.42),交互P=0.02。
  • PASCAL分类不太可能、可能、很可能者的HR分别为1.14(95%CI 0.53-2.46)、0.38(95%CI 0.22-0.65)、0.10(95%CI 0.03-0.35),交互P=0.003。
  • 2年绝对风险降低在PASCAL不太可能、可能、很可能组分别为-0.7%(95%CI -4.0%至2.6%)、2.1%(95%CI 0.6%-3.6%)、2.1%(95%CI 0.9%-3.4%)。
  • 封堵相关不良事件在PASCAL不太可能组总体更高;随机化45天后新发心房颤动的绝对风险增加在不太可能、可能、很可能组分别为4.41%(95%CI 1.02%-7.80%)、1.53%(95%CI 0.33%-2.72%)、0.65%(95%CI -0.41%-1.71%)。

证据类型、等级与局限

  • 证据类型:基于6项随机临床试验个体患者数据的汇总分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,应用PASCAL分类系统有潜力指导卵圆孔未闭相关卒中患者的个体化决策;封堵术的卒中风险降低在不同PASCAL分类组间存在差异,PASCAL不太可能组封堵相关不良事件总体更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patent foramen ovale (PFO)-associated strokes comprise approximately 10% of ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke recurrence risk overall, the best treatment for any individual is often unclear.

OBJECTIVE: To evaluate heterogeneity of treatment effect of PFO closure on stroke recurrence based on previously developed scoring systems.

DESIGN, SETTING, AND PARTICIPANTS: Investigators for the Systematic, Collaborative, PFO Closure Evaluation (SCOPE) Consortium pooled individual patient data from all 6 randomized clinical trials that compared PFO closure plus medical therapy vs medical therapy alone in patients with PFO-associated stroke, and included a total of 3740 participants. The trials were conducted worldwide from 2000 to 2017.

EXPOSURES: PFO closure plus medical therapy vs medical therapy alone. Subgroup analyses used the Risk of Paradoxical Embolism (RoPE) Score (a 10-point scoring system in which higher scores reflect younger age and the absence of vascular risk factors) and the PFO-Associated Stroke Causal Likelihood (PASCAL) Classification System, which combines the RoPE Score with high-risk PFO features (either an atrial septal aneurysm or a large-sized shunt) to classify patients into 3 categories of causal relatedness: unlikely, possible, and probable.

MAIN OUTCOMES AND MEASURES: Ischemic stroke.

RESULTS: Over a median follow-up of 57 months (IQR, 24-64), 121 outcomes occurred in 3740 patients. The annualized incidence of stroke with medical therapy was 1.09% (95% CI, 0.88%-1.36%) and with device closure was 0.47% (95% CI, 0.35%-0.65%) (adjusted hazard ratio [HR], 0.41 [95% CI, 0.28-0.60]). The subgroup analyses showed statistically significant interaction effects. Patients with low vs high RoPE Score had HRs of 0.61 (95% CI, 0.37-1.00) and 0.21 (95% CI, 0.11-0.42), respectively (P for interaction = .02). Patients classified as unlikely, possible, and probable using the PASCAL Classification System had HRs of 1.14 (95% CI, 0.53-2.46), 0.38 (95% CI, 0.22-0.65), and 0.10 (95% CI, 0.03-0.35), respectively (P for interaction = .003). The 2-year absolute risk reduction was -0.7% (95% CI, -4.0% to 2.6%), 2.1% (95% CI, 0.6%-3.6%), and 2.1% (95% CI, 0.9%-3.4%) in the unlikely, possible, and probable PASCAL categories, respectively. Device-associated adverse events were generally higher among patients classified as unlikely; the absolute risk increases in atrial fibrillation beyond day 45 after randomization with a device were 4.41% (95% CI, 1.02% to 7.80%), 1.53% (95% CI, 0.33% to 2.72%), and 0.65% (95% CI, -0.41% to 1.71%) in the unlikely, possible, and probable PASCAL categories, respectively.

CONCLUSIONS AND RELEVANCE: Among patients aged 18 to 60 years with PFO-associated stroke, risk reduction for recurrent stroke with device closure varied across groups classified by their probabilities that the stroke was causally related to the PFO. Application of this classification system has the potential to guide individualized decision-making.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kent DM, Saver JL, Kasner SE, et al. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. JAMA. 2021. PMID: 34905030. doi:10.1001/jama.2021.20956

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。